Carisma Therapeutics Inc. is a biotechnology company focused on macrophage and monocyte engineering to develop therapies for liver fibrosis and cancer. Its proprietary CAR-M platform uses chimeric antigen receptors to redirect macrophages against tumor-associated antigens. Key candidates include CT-2401 (liver fibrosis, mRNA/LNP approach) and CT-1119 (mesothelin-positive solid tumors). Following strategic reviews in 2024-2025, the company paused R&D and is exploring strategic alternatives including asset sales, partnerships, or a company merger.
Q2 FY2026 — expected 2026-09-12
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-03-31 | 2024-12-31 | 0001628280-25-015673 | EDGAR | 105K words |
| 2024-04-01 | 2023-12-31 | 0001485003-24-000005 | EDGAR | — |
| 2023-02-28 | 2022-12-31 | 0001485003-23-000090 | EDGAR | — |
| 2022-02-28 | 2021-12-31 | 0001485003-22-000033 | EDGAR | — |
| 2021-03-15 | 2020-12-31 | 0001485003-21-000044 | EDGAR | — |
| 2020-03-16 | 2019-12-31 | 0001485003-20-000038 | EDGAR | — |
| 2019-03-01 | 2018-12-31 | 0001485003-19-000015 | EDGAR | — |
| 2018-04-02 | 2017-12-31 | 0001485003-18-000034 | EDGAR | — |
| 2017-03-24 | 2016-12-31 | 0001485003-17-000018 | EDGAR | — |
| 2016-03-25 | 2015-12-31 | 0001485003-16-000068 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001104659-25-110444 | EDGAR | 23K words |
| 2025-08-07 | 2025-06-30 | 0001628280-25-038922 | EDGAR | — |
| 2025-05-13 | 2025-03-31 | 0001628280-25-025144 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0001485003-24-000020 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0001485003-24-000015 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0001485003-24-000009 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0001485003-23-000119 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0001485003-23-000116 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0001104659-23-058778 | EDGAR | — |
| 2022-11-07 | 2022-09-30 | 0001485003-22-000156 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0001485003-22-000108 | EDGAR | — |
| 2022-05-09 | 2022-03-31 | 0001485003-22-000063 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2025-12-05 | 0001104659-25-118863 | EDGAR | 1K words |
| 2025-10-15 | 0001104659-25-099740 | EDGAR | — |
| 2025-10-09 | 0001104659-25-098404 | EDGAR | — |
| 2025-09-18 | 0001104659-25-091064 | EDGAR | — |
| 2025-08-29 | 0001104659-25-085705 | EDGAR | — |
| 2025-08-08 | 0001104659-25-075680 | EDGAR | — |
| 2025-07-15 | 0001104659-25-068098 | EDGAR | — |
| 2025-06-23 | 0001104659-25-061397 | EDGAR | — |
| 2025-06-12 | 0001104659-25-058622 | EDGAR | — |
| 2025-04-16 | 0001104659-25-035517 | EDGAR | — |
350 total filings indexed. 318 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001485003 |
| Ticker | CARM |
| Exchange | OTC |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report